Clinical trial tests combination antibody therapy in adults with advanced cancer

CS1002 plus CS1003 (nofazinlimab) had a manageable safety profile across a broad dosing range and showed promising anti-tumor activity.

2024-02-26

(Press-News.org) In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Both medications tested in the trial support immune responses against tumor cells. CS1002 increases the activation and proliferation of T immune cells by binding to a T cell receptor called CTLA-4. CS1003, also called nofazinlimab, blocks the programmed cell death protein 1 that is expressed on various types of immune cells and plays a role in suppressing the immune system.

In this first-in-human multicenter, open-label study conducted from April 26, 2018 to January 18, 2022 at 9 study sites in Australia and China, phase Ia involved monotherapy dose-escalation (Part 1), which was followed by phase Ib combination therapy dose escalation (Part 2) and expansion (Part 3). Various dosing schedules of CS1002 (0.3, 1, or 3 mg/kg once every 3 weeks, or 3 mg/kg once every 9 weeks) were evaluated with 200 mg CS1003 once every 3 weeks.

Parts 1, 2, and 3 of the trial included 13, 18, and 61 patients, respectively, who had advanced/metastatic solid, relapsed, or refractory tumors. During treatment, investigators did not observe any dose-limiting toxicities or a maximum tolerated dose. Treatment-related side effects such as diarrhea, fatigue, and rash were reported in 30.8%, 83.3%, and 75.0% of patients in Parts 1, 2, and 3, respectively. Serious side effects such as intestinal inflammation and severe skin reactions were experienced by 15.4%, 50.0%, and 18.3% of patients in each part.

Of 61 patients evaluable for treatment efficacy, 23 (37.7%) with different types of tumors experienced a positive response. Higher response rates occurred with conventional and high-dose CS1002 regimens (1 mg/kg once every 3 weeks or 3 mg/kg once every 9 weeks) compared with low-dose CS1002 (0.3 mg/kg once every 3 weeks) in certain cancers such as melanoma and skin cancer.

“CS1002 in combination with CS1003 had manageable safety profile across a broad dosing range and showed promising anti-tumor activities across CS1002 dose levels when combined with CS1003,” the investigators wrote. “This supports further assessment of CS1002 in combination with CS1003 for the treatment of solid tumors.”

Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com

Full Citation:
“Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.” Sarwan Bishnoi, Dusan Kotasek, Morteza Aghmesheh, Thomas Yau, Rasha Cosman, Amy Prawira, Maggie Moore, Stephen L. Chan, Andrew Mant, Richard Eek, Robert Zielinski, Rila Su, Zhaoxuan Pan, Yiding Ma, Fei Li, Peiqi Li, and Archie N. Tse. CANCER; Published Online: February 26, 2024 (DOI: 10.1002/cncr.35226).

URL Upon Publication: http://doi.wiley.com/10.1002/cncr.35226

About the Journal    
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on Twitter @JournalCancer and Instagram @ACSJournalCancer, and stay up to date with the American Cancer Society Journals on LinkedIn.

About Wiley     
Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world's most important challenges. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, Twitter, LinkedIn and Instagram.

END

ELSE PRESS RELEASES FROM THIS DATE:

Birds and bee lessons as Pacific field trips also solve 'Michener's mystery'

2024-02-26

Eight new Pacific bee species and new insights into Fijian bird behaviour on Viti Levu Island have been described in new scientific studies led by Flinders University. The studies, both funded by field work supported by the Australian Government’s New Colombo Mobility Plan Program, highlight the potential for species discovery, ecological and conservation knowledge and cultural engagement from Asia-Pacific research collaborations. In the past 10 years, Australian Government-funded Flinders University field trips have worked closely ...

Can they hear you now? Kids increasingly exposed to noise health risks via earbuds and headphones

2024-02-26

ANN ARBOR, Mich. – While it’s not surprising to spot teens wearing headphones and earbuds, it’s also becoming a widespread trend among younger children, a national poll suggests. Two in three parents say their child ages 5-12 uses personal audio devices, with half of parents of children ages 5-8 reporting elementary-aged kids use a device. Among parents whose children use headphones and earbuds, half say kids spend at least an hour a day using them while one in six say a typical ...

How did a tiny bee get to French Polynesia? Eight new species help solve a scientific mystery

2024-02-26

In 1934, American entomologist Elwood Zimmerman, then an undergraduate student at Berkeley, participated in the ‘Mangarevan expedition’ to Polynesia. Among the samples he collected were three tiny (4 mm long), orange-brown solitary bees found on tahetahe flowers in the Tuamotu Archipelago. The specimens rested undisturbed in the Bernice P Bishop Museum of Honolulu until 1965, when the famous bee specialist Prof Charles Michener examined them. He described them as a species new to science: Hylaeus tuamotuensis, or Tuamotu’s masked bee, in the family ...

Many older adults receiving home care do not receive palliative care before death

2024-02-26

Many older adults receiving home care do not receive any palliative home care before death, suggesting we need better methods to identify people who need this support, according to new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.221513. "Palliative care is an essential component of a holistic, comprehensive and patient-centred approach to care for all people with a life-limiting illness from the time of diagnosis with the disease," said Dr. Amy Hsu, investigator at the Bruyère Research Institute and faculty in the Department of Family Medicine at the ...

Reforestation schemes are not enough to recover the carbon created by harvesting wood, research suggests

2024-02-26

Forests have a critical role to play in capturing and storing carbon from the Earth’s atmosphere – but some models exaggerate their carbon removal potential by almost three-fold, according to a leading professor of forest economics. Global Forest Carbon: Policy, Economics and Finance by Runsheng Yin from Michigan State University emphasizes the value of nature-based solutions to the climate crisis but calls for significant changes to the way carbon credits from reforestation, afforestation, and improved forest management are calculated. He has found that current modeling of local ...

Antidepressant dispensing to adolescents and young adults surges during pandemic

2024-02-26

Antidepressant dispensing to adolescents and young adults increased sharply after the COVID-19 pandemic began – particularly among females – a new study finds. While a growing number of young people ages 12 to 25 were receiving antidepressants before the pandemic, the antidepressant dispensing rate rose nearly 64% faster after March 2020, according to Michigan Medicine led findings in Pediatrics. “Antidepressant dispensing to adolescents and young adults was already high and rising before ...

Healthcare leaders plea to reinstate the Canadian hypertension control program to prevent death and disability

2024-02-26

Philadelphia, February 26, 2024 – A passionate plea for the re-establishment of Canada's health coalition focused on hypertension prevention and control appears as an editorial in the Canadian Journal of Cardiology, published by Elsevier. "We need a national hypertension control program to prevent death and disability," according to prominent healthcare leaders. Lead author of the editorial Norm R.C. Campbell, MD, Department of Medicine, University of Calgary, explains, "Hypertension is a leading cause of death and disability in Canada; globally it causes about one in five deaths (19.2%). However, ...

Drug limits dangerous reactions to allergy-triggering foods, Stanford Medicine-led study of kids finds

2024-02-25

A drug can make life safer for children with food allergies by preventing dangerous allergic responses to small quantities of allergy-triggering foods, according to a new study led by scientists at the Stanford School of Medicine. The research will be published Feb. 25 in the New England Journal of Medicine. The findings suggest that regular use of the drug, omalizumab, could protect people from severe allergic responses, such as difficulty breathing, if they accidentally eat a small amount of a food they are allergic to. “I’m excited that we have a promising ...

Measuring the properties of light: Scientists realise new method for determining quantum states

2024-02-25

Scientists at Paderborn University have used a new method to determine the characteristics of optical, i.e. light-based, quantum states. For the first time, they are using certain photon detectors - devices that can detect individual light particles - for so-called homodyne detection. The ability to characterise optical quantum states makes the method an essential tool for quantum information processing. Precise knowledge of the characteristics is important for use in quantum computers, for example. The results have now been published in the specialist journal "Optica Quantum". "Homodyne detection is a method frequently ...

For faster access to gene and cell therapies in Europe

2024-02-25

Gene and cell therapies are among the most important innovations in the healthcare sector. And they reflect advances in science and technology. They have the potential to radically reshape the treatment of cancer, autoimmune diseases, neurodegenerative disorders, and many rare genetic conditions. But the path to approval and clinical use of these products is long and often fraught with difficulty. That was the reason the European University Hospital Alliance (EUHA) founded the European Center for Cell and Gene Cancer Therapies (EUCCAT) four years ago. The center’s aim is to facilitate the clinical use of ATMPs developed at higher education institutions and further ...

Clinical trial tests combination antibody therapy in adults with advanced cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: